Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTENT: Exemestane and Sunitinib in HR+ Metastatic Breast Cancer
NCT00905021Phase 2Terminated
- Sponsor
- Baylor Breast Care Center
- Start
- Mar 2010
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in breast cancer, sponsored by Baylor Breast Care Center. Primary endpoint: Progression-Free Survival at 12 weeks. Started Mar 2010; status: terminated.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00905021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00905021.